1xv9: Difference between revisions

New page: left|200px<br /> <applet load="1xv9" size="450" color="white" frame="true" align="right" spinBox="true" caption="1xv9, resolution 2.7Å" /> '''crystal structure of...
 
No edit summary
Line 1: Line 1:
[[Image:1xv9.gif|left|200px]]<br />
[[Image:1xv9.gif|left|200px]]<br /><applet load="1xv9" size="350" color="white" frame="true" align="right" spinBox="true"  
<applet load="1xv9" size="450" color="white" frame="true" align="right" spinBox="true"  
caption="1xv9, resolution 2.7&Aring;" />
caption="1xv9, resolution 2.7&Aring;" />
'''crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-dione.'''<br />
'''crystal structure of CAR/RXR heterodimer bound with SRC1 peptide, fatty acid, and 5b-pregnane-3,20-dione.'''<br />


==Overview==
==Overview==
The X-ray crystal structure of the human constitutive androstane receptor, (CAR, NR1I3)/retinoid X receptor alpha (RXRalpha, NR2B1) heterodimer sheds, light on the mechanism of ligand-independent activation of transcription, by nuclear receptors. CAR contains a single-turn Helix X that restricts, the conformational freedom of the C-terminal AF2 helix, favoring the, active state of the receptor. Helix X and AF2 sit atop four amino acids, that shield the CAR ligand binding pocket. A fatty acid ligand was, identified in the RXRalpha binding pocket. The endogenous RXRalpha ligand, combined with stabilizing interactions from the heterodimer interface, served to hold RXRalpha in an active conformation. The structure suggests, that upon translocation, CAR/RXRalpha heterodimers are preorganized in an, active conformation in cells such that they can regulate transcription of, target genes. Insights into the molecular basis of CAR constitutive, activity can be exploited in the design of inverse agonists as drugs for, treatment of obesity.
The X-ray crystal structure of the human constitutive androstane receptor (CAR, NR1I3)/retinoid X receptor alpha (RXRalpha, NR2B1) heterodimer sheds light on the mechanism of ligand-independent activation of transcription by nuclear receptors. CAR contains a single-turn Helix X that restricts the conformational freedom of the C-terminal AF2 helix, favoring the active state of the receptor. Helix X and AF2 sit atop four amino acids that shield the CAR ligand binding pocket. A fatty acid ligand was identified in the RXRalpha binding pocket. The endogenous RXRalpha ligand, combined with stabilizing interactions from the heterodimer interface, served to hold RXRalpha in an active conformation. The structure suggests that upon translocation, CAR/RXRalpha heterodimers are preorganized in an active conformation in cells such that they can regulate transcription of target genes. Insights into the molecular basis of CAR constitutive activity can be exploited in the design of inverse agonists as drugs for treatment of obesity.


==Disease==
==Disease==
Line 11: Line 10:


==About this Structure==
==About this Structure==
1XV9 is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with CI2 and F15 as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://ispc.weizmann.ac.il/oca-bin/ocashort?id=1XV9 OCA].  
1XV9 is a [http://en.wikipedia.org/wiki/Protein_complex Protein complex] structure of sequences from [http://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] with <scene name='pdbligand=CI2:'>CI2</scene> and <scene name='pdbligand=F15:'>F15</scene> as [http://en.wikipedia.org/wiki/ligands ligands]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1XV9 OCA].  


==Reference==
==Reference==
Line 17: Line 16:
[[Category: Homo sapiens]]
[[Category: Homo sapiens]]
[[Category: Protein complex]]
[[Category: Protein complex]]
[[Category: Lambert, M.H.]]
[[Category: Lambert, M H.]]
[[Category: Moore, J.T.]]
[[Category: Moore, J T.]]
[[Category: Moore, L.B.]]
[[Category: Moore, L B.]]
[[Category: Waitt, G.M.]]
[[Category: Waitt, G M.]]
[[Category: Warren, E.N.]]
[[Category: Warren, E N.]]
[[Category: Weinert, E.E.]]
[[Category: Weinert, E E.]]
[[Category: Williams, J.D.]]
[[Category: Williams, J D.]]
[[Category: Willson, T.M.]]
[[Category: Willson, T M.]]
[[Category: Wisely, B.B.]]
[[Category: Wisely, B B.]]
[[Category: Xu, R.X.]]
[[Category: Xu, R X.]]
[[Category: CI2]]
[[Category: CI2]]
[[Category: F15]]
[[Category: F15]]
Line 34: Line 33:
[[Category: src1]]
[[Category: src1]]


''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 20:11:23 2007''
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Thu Feb 21 15:59:00 2008''

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

OCA